JAZZ Sep 2024 125.000 call
| Previous close | 2.9000 |
| Open | 3.7000 |
| Bid | 1.1000 |
| Ask | 4.9000 |
| Strike | 125.00 |
| Expiry date | 2024-09-20 |
| Day's range | 2.9000 - 3.3300 |
| Contract range | N/A |
| Volume | |
| Open interest | 68 |
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:
- PR Newswire
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). Under the Prescription Drug User Fee Act (PDUFA), FDA has set a target action date
- PR Newswire
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences industry across several regions in the U.S. – and partner with nonprofits – to disrupt the cycle of po
